智通财经APP获悉，药明合联(02268)再涨超6%，截至发稿，涨6.35%，报58.65港元，成交额1.69亿港元。
消息面上，药明合联日前公布，公司已议决动用最多1亿美元的内部资金，委托专业受托人在公开市场购买公司股份。公司指出，股份目前的交易价格并未反映其内在价值或实际业务前景。值得一提的是，截至2025年末，药明合联未完成订单总量为14.89亿美元，同比增长50.3%，充沛的未完成订单为未来业绩提供保障。
里昂此前研报指出，药明合联重申其2025至2030年收入年均复合增长率目标为30%至35%，2030年CMO组合目标为20%，2025年在手订单增长50%。该行认为这增强公司的盈利可见性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.